AFT expanded its co-operation with Hikma Pharmaceuticals to extend its license for Maxigesic/Combogesic IV, the intravenous form of the pain relief medicine, to Saudi Arabia, Iraq, and Jordan. Hikma is the licensee of the medicine in the US where it was recently launched.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 NZD | +0.65% | -1.59% | -11.71% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.71% | 192M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AFT Stock
- News AFT Pharmaceuticals Limited
- Aft Expands Its Co-Operation with Hikma Pharmaceuticals